TOP 20

Top 20 Biopharma Deal Terminations of 2025

Shots: Biopharma dealmaking in 2025 continued to face significant headwinds, with collaborations frequently collapsing due to strategic reprioritization, fierce competitive pressures, unfavorable clinical readouts, and failure to meet key closing conditions highlighting the inherent uncertainty and capital risk embedded in innovation-driven partnerships The year underscored a clear dominance of R&D-focused collaborations and licensing agreements,…

2 days ago

Top 20 Biopharma Companies of 2026

Shots: The biopharma industry is a multi-hundred-billion-dollar market, with a projected compound annual growth rate (CAGR) of 8.6%, the global biopharma market is expected to reach $1.41T by 2034. Eli Lilly and Co. ranked first with $65.17B, followed by Pfizer ($61.19B) and AbbVie ($61.16B), reflecting strong market concentration among large-cap innovators with diversified, high-value portfolios …

April 10, 2026

Top 20 Healthcare IPOs of 2025

Shots: The Healthcare IPOs in 2025 underscore sustained investor confidence across biotech, medtech, digital health, and AI-enabled healthcare companies, signaling robust capital deployment into next-generation therapies, advanced diagnostics, and evolving healthcare delivery models worldwide. IPO activity was dominated by high-value raises, with Medline Industries ($7.2B) leading by a wide margin, followed by Caris Life Sciences…

March 27, 2026

Top 20 Life Sciences Deals of 2025

Shots: From AI-powered discovery to next-generation biologics and gene editing, 2025 was a blockbuster year for life sciences dealmaking. Pharma and biotech companies signed multibillion-dollar partnerships and acquisitions to accelerate innovation across oncology, cardiometabolic diseases, neurology, and rare disorders. Platform technologies dominated the deal landscape, with big pharma securing access to cutting-edge modalities from bispecific…

March 20, 2026

PharmaShots Women’s Day Special: 20 Leaders Redefining Healthcare

Shots: Women leaders are reshaping the healthcare industry, bringing visionary leadership, scientific expertise, and strategic insight to traditionally male-dominated spaces From biotech innovation to global pharmaceutical enterprises, these trailblazers are driving transformative solutions, advancing patient care, and championing inclusive workplace cultures PharmaShots spotlights 20 extraordinary women leaders in healthcare, celebrating their achievements, impact, and inspiring journeys that…

March 8, 2026

Top 20 Radiopharmaceutical Companies of 2026

Shots: The Top 20 Radiopharma Companies of 2026, ranked by market capitalization, represent a powerful mix of global pharmaceutical leaders and agile innovators transforming radioligand therapies, alpha-emitters, and copper-based theranostics into pillars of modern oncology. What was once niche science is now redefining precision cancer care. Flagship therapies such as Lutathera, Pluvicto, Pylarify, Illuccix/Gozellix, Xofigo,…

February 27, 2026

Top 20 Emerging Animal Health Companies Worldwide in 2026

Top 20 Emerging Animal Health Companies Worldwide in 2026 Shots: Emerging companies in the animal health sector are gaining ground in livestock, poultry, equine, and companion animal markets. Small and mid-sized innovators offer affordable care models, targeted biologics, and sustainable solutions for global needs These firms bolster their positions via portfolio growth, partnerships, acquisitions, and…

February 20, 2026

Top 20 M&A of 2025 by Total Deal Value

Shots: 2025 pharma M&A was defined by fewer but more transformational deals, with companies prioritizing commercial-stage assets, late-stage pipelines, and platform technologies capable of reshaping long-term growth and strengthening core therapeutic franchises The year’s momentum was led by three standout transactions, J&J’s $14.6B acquisition of Intra-Cellular Therapies, Novartis’ $12B deal for Avidity Biosciences, and Merck’s…

January 30, 2026

20 AI Healthcare Companies of 2025

Shots: AI is revolutionizing healthcare, reshaping drug discovery, protein design, and precision therapeutics. Companies are now tackling previously “undruggable” targets and moving treatments through development pipelines faster than ever The AI in the healthcare market is exploding. From a valuation of $26.57B in 2024, it is projected to reach $505.59B by 2033, growing at a CAGR of 38.8%. This rapid…

December 18, 2025

Top 20 Animal Health Companies of 2025

Shots: Animal health companies remain fundamental to global veterinary care and modern food production, driving innovation across pharmaceuticals, vaccines, diagnostics, and digital technologies that support the health of both companion animals and livestock The sector continues to deliver robust, steady growth, fueled by rising pet ownership, increasing demand for safe and sustainable protein, and rapid…

December 12, 2025